~~CORRECTED VERSION*~~ CORRECTED VERSION**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

9904096-6
IPO COPY

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 39/12, 39/193, C12N 7/01

A1

(11) International Publication Number: WO 98/37911

(43) International Publication Date: 3 September 1998 (03.09.98)

(21) International Application Number: PCT/US98/03894

(22) International Filing Date: 2 March 1998 (02.03.98)

(30) Priority Data:

08/807,445	28 February 1997 (28.02.97)	US
09/007,664	15 January 1998 (15.01.98)	US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

US	08/807,445 (CIP)
Filed on	28 February 1997 (28.02.97)
US	09/007,664 (CIP)
Filed on	15 January 1998 (15.01.98)

(71) Applicants *(for all designated States except US)*: ORAVAX, INC. [US/US]; 38 Sidney Street, Cambridge, MA 02139 (US). ST. LOUIS UNIVERSITY [US/US]; 221 North Grand Boulevard, St. Louis, MO 63103 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: CHAMBERS, Thomas, J. [US/US]; 828 Twin Pine Drive, St. Louis, MO 63122 (US). MONATH, Thomas, P. [US/US]; 21 Finn Road, Harvard, MA 01451 (US). GUIRAKHOO, Farshad [AT/US]; 39 Chestnut Street, Melrose, MA 02176 (US).

(74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CHIMERIC FLAVIVIRUS VACCINES

(57) Abstract

A chimeric live, infectious, attenuated virus, containing a yellow fever virus, in which the nucleotide sequence for a prM–E protein is either deleted, truncated, or mutated, so that functional prM–E protein is not expressed, and integrated into the genome of the yellow fever virus, a nucleotide sequence encoding a prM–E protein of a second, different flavivirus, so that the prM–E protein of the second flavivirus is expressed.